GSK - GSK plc
After hours:
| Previous close | 33.80 |
| Open | 33.95 |
| Bid | 34.00 x 1100 |
| Ask | 34.16 x 3200 |
| Day's range | 33.88 - 34.26 |
| 52-week range | 28.47 - 44.75 |
| Volume | |
| Avg. volume | 2,889,204 |
| Market cap | 69.84B |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | 12.49 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.39 (4.12%) |
| Ex-dividend date | 18 May 2023 |
| 1y target est | N/A |
- Simply Wall St.
Investors in GSK (LON:GSK) have unfortunately lost 19% over the last year
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. While...
- Simply Wall St.
Interested In GSK's (LON:GSK) Upcoming UK£0.14 Dividend? You Have Four Days Left
GSK plc ( LON:GSK ) is about to trade ex-dividend in the next 4 days. The ex-dividend date is one business day before...
- Yahoo Finance UK
Trending tickers: GSK | THG | Beazley | Disney
The latest investor updates on stocks that are trending on Friday.
- Yahoo Finance UK
Wall Street loses ground as FTSE 100 closes higher on UK economy growth
FTSE 100 closes the week higher as the UK economy returned to growth.
- Motley Fool
The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer
Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are two healthcare companies aiming to produce a vaccine for the respiratory syncytial virus (RSV). In trials, their vaccine candidates have been proving highly effective, and it may not be long before these COVID-19 vaccine makers are fighting for market share again -- this time in the RSV market. The Food and Drug Administration (FDA) recently approved an RSV vaccine, and it wasn't from either of these two companies.
- Simply Wall St.
GSK plc (LON:GSK) is favoured by institutional owners who hold 82% of the company
Key Insights Significantly high institutional ownership implies GSK's stock price is sensitive to their trading actions...
- Yahoo Finance Video
GSK’s vaccine against RSV wins FDA approval
Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss the FDA’s approval of GlaxoSmithKline’s (GSK) vaccine against RSV.
- Yahoo Finance
Pfizer to shift focus to new products amid decline in COVID sales
Pfizer reported strong earnings for the first quarter of the year, despite a decrease in COVID product demand. However, investors are wary of the company's anticipated product launches this year.
- Yahoo Finance Video
Why the human genome could be health care’s holy grail
23andMe Co-founder & CEO Anne Wojcicki says we’ve only seen the tip of the iceberg for human genomics and DNA research. “Look at all the explosion of all these new technologies with gene therapy, with CRISPR (CRSP), with RNA technologies and understanding the human genome,” Wojcicki told Yahoo Finance at the Milken Global Conference in Beverly Hills, California. Wojcicki says she’s ‘disappointed’ in the lack of progress around genomics, despite having just crossed a significant milestone, 20 years since the first complete sequencing of the human genome. “I think part of the reason is that genetics tells you a lot about what you're at risk for and it doesn't necessarily financially pay to get you that preventative information and to intervene in that way versus just treating people once they have a disease.” The 23andMe (ME) CEO also says they are looking into building new partnerships with pharmaceutical giants once the company’s partnership with GlaxoSmithKline (GSK) ends in July. Interview Highlights: 1:29 How genetics can tell us more about human diversity 2:20 Why 23andMe CEO is ‘disappointed’ about genome adoption 5:00 Wojcicki on 23andMe partnership with pharma giant GSK 7:15 Genetics needs to be part of medical school training 8:26 What’s next for 23andMe
- Yahoo Finance
23andMe CEO: We see more opportunities in DNA partnerships
23 & Me CEO Anne Wojicki reveals the next key opportunity for her company.
- Motley Fool
Was This Acquisition a Savvy Play by This Big Pharma Stock?
Earlier this month, U.K.-based drugmaker GSK (NYSE: GSK) reached a deal to buy Canadian biotech company Bellus Health (NASDAQ: BLU) for $2 billion in cash. Should GSK's deal for Bellus Health be approved by regulatory authorities and a two-thirds majority of the latter's shareholders, the former will pick up a promising drug candidate, camlipixant, that aims to treat refractory chronic cough (RCC). Surprisingly, there are no approved therapies for RCC in the United States or the European Union.
- Zacks
GSK (GSK) Tops Q1 Earnings Estimates
Glaxo (GSK) delivered earnings and revenue surprises of 5.88% and 1.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Yahoo Finance UK
Trending tickers: Microsoft | Alphabet | First Republic | Meta | GSK
A look at the stocks making headlines on Wednesday.
- Motley Fool
Why Shares of Bellus Health Skyrocketed This Week
Shares of Bellus Health (NASDAQ: BLU) jumped 105.1% this week as of Thursday afternoon, according to data provided by S&P Global Market Intelligence. The company, which received a $2 billion buyout offer from GSK (formerly known as GlaxoSmithKline) (NYSE: GSK), closed at $7.06 last week and reached a new 52-week high at $14.50 on Tuesday. The attraction for GSK is camlipixant, Bellus' late-stage pipeline candidate to treat adults with refractory chronic cough (RCC).
- Motley Fool
Why BELLUS Health Stock Is Rocketing Higher Today
What happened Shares of BELLUS Health (NASDAQ: BLU) were up by a whopping 98.9% as of 10:19 a.m. ET Tuesday morning. The big gain came in response to a $2 billion buyout agreement with British pharma giant GSK (NYSE: GSK).
- Motley Fool
Is Arrowhead Pharmaceuticals a Buy Now?
The clinical-stage drug developer is attracting a lot of positive attention from investment bank analysts.
- Motley Fool
Can Pfizer Beat GSK and Moderna in This $10 Billion Market?
Pfizer (NYSE: PFE) and GSK (NYSE: GSK) have competed against each other for years. Moderna (NASDAQ: MRNA) is a more recent rival, with its COVID-19 vaccine, SpikeVax, going head to head with Pfizer's Comirnaty. Can Pfizer beat GSK and Moderna in this $10 billion market?
- Motley Fool
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) were up as much as 9.7% early Tuesday after the clinical-stage biotech announced that it had reached an agreement with GSK (NYSE: GSK) to return the rights to Adaptimmune's PRAME and NY-ESO cell therapy programs. Adaptimmune focuses on therapies to treat cancer in solid tumors through its SPEAR (for Specific Peptide Enhanced Affinity Receptor) T-cell platform. The company has four SPEAR T-cells in trials: MAGE-A10, MAGE-A4, AFP, and NY-ESO.
- Motley Fool
Could This Move by Johnson & Johnson Equal Billions for Moderna?
What does big pharma Johnson & Johnson (NYSE: JNJ) have in common with biotech Moderna (NASDAQ: MRNA)? Last week, however, Johnson & Johnson said it would discontinue its adult RSV program. Could the J&J news eventually translate into billions of dollars for Moderna?
- Motley Fool
Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?
No vaccine has been approved to prevent respiratory syncytial virus (RSV), but there are more than 30 different RSV vaccine candidates in clinical trials, according to PATH, a global health organization. Research from the Centers for Disease Control and Prevention (CDC) estimate that between 60,000 and 160,000 adults 65 and older are hospitalized each year with RSV, and 6,000 to 10,000 older adults die because of it. One to two out of every 100 children younger than 6 months of age with an RSV infection may need to be hospitalized.
- Zacks
Protagonist Therapeutics (PTGX) Soars 51.9%: Is Further Upside Left in the Stock?
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Motley Fool
Could This Be the Next Blockbuster Vaccine for This Big Pharma Stock?
Earlier this month, GSK's (NYSE: GSK) older-adult vaccine candidate for respiratory syncytial virus (RSV) moved one step closer to approval. The U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee voted unanimously (12 to 0) in favor of the vaccine's efficacy and 10 to 2 in favor of its safety. With a decision expected from the FDA by May, the vaccine candidate could launch in time for the next RSV season.
- Motley Fool
My 3 Biggest Stock Market Predictions for March
Albemarle (NYSE: ALB) just came out with its full-year and fourth-quarter earnings, and the mining company's decision to raise prices for lithium is paying off. Knowing that automakers increasingly need lithium for the batteries in electric vehicles, the move was simply a case of higher demand raising prices. The company reported fourth-quarter revenue of $2.6 billion, up 193% year over year.
- Zacks
GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod
GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.
- Zacks
GSK (GSK) Q4 Earnings and Revenues Top Estimates
Glaxo (GSK) delivered earnings and revenue surprises of 8.47% and 4.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
